Drug product performance, in vitro

Generic Drug Product Development: Solid Oral Dosage Forms

Volumn , Issue , 2014, Pages 187-209

  Sathe, Pradeep M ^a   Raw, Andre S ^a   Ouderkirk, Larry A ^a   Yu, Lawrence X ^a   Hussain, Ajaz S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866378663     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (55)

1. The US Pharmacopeia/National Formulary, USP 26-NF 21. Rockville, MD: United States Pharmacopeial Convention Inc., 2002.
2. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Rockville, MD: Food and Drug Administration/Center for Drug Evaluation and Research, 1997.
3. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. Rockville, MD: Food and Drug Administration/Center for Drug Evaluation and Research, 2003.
4. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation and Application of In vitro/In vivo Correlations. Rockville, MD: Food and Drug Administration/Center for Drug Evaluation and Research, 1997.
5. Food and Drug Administration/Center for Drug Evaluation and Research Data Standards Manual. Rockville, MD: Food and Drug Administration/Center for Drug Evaluation and Research, 1992:18.
6. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). 23rd ed. Rockville, MD: US Department of Health and Human Services/Food and Drug Administration, 2003.
7. Abdou HM. Evolution of Dissolution Testing, Theory of Dissolution, Theoretical Concepts for the Release of a Drug from Dosage Forms and Factors Affecting Rate of Dissolution. Dissolution Bioavailability & Bioequivalence. Easton, PA: Mack Publishing Company, 1989:1-105.
8. Noyes A, Whitney W. The rate of solution of solid substances in their own solutions. J Amer Chem Soc 1897; 19(12):930-934.
9. Brunner L, Tolloczko S. Über die auflösungsgeschwindingkeit fester körper. Zeitschrifft für Physiologische Chemie 1900; 35(3):283-290.
10. Nernst W. Theorie der reaktionsgeschwindigkeit in heterogenen Systemen. Zeitschrifft für Physiologische Chemie 1904; 47(1):52-55.
11. Yu LX, Amidon GL. Analytical solutions to mass transfer In: Amidon GL, Lee PI, Topp EM, eds. Transport Processes in Pharmaceutical Systems, NewYork: Marcel Dekker, Inc., 1999:23-54.
12. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Del Rev 2001; 46(1-3):75-87.
13. Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm Res 1995; 12(7): 945-954.
14. Yu LX, Furness MS, Raw A, Woodland Outlaw KP, Nashed NE, Ramos E, Miller SPF, Adams RC, Fang F, Patel RM, Holcombe FO Jr, Chiu Y, Hussain AS, Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharm Res 2003; 20(4):531-536.
15. Grant DJW, Higuchi T. Solubility Behavior of Organic Compounds, New York: John Wiley & Sons, 1990.
16. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 2000; 17(4):397-404.
17. Aguiar AJ, Krc J, Kinkel AW, Samyn JC. Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. J Pharm Sci 1967; 56(7):847-853.
18. Morris KR, Fakes MG, Thakur AB, Newman AW, Singh AK, Venit JJ, Spagnualo CJ, Abu TM. An integrated approach to the selection of optimal salt form for a new drug candidate. Int J of Pharm 1994;105: 209-217.
19. Stavchansky R, McGinity J. Bioavailability and tablet technology. In: Lieberman HA, Lachman L, Schwartz JB, eds. Pharmaceutical Dosage Forms: Tablets. Vol. 2. New York: Marcel Dekker 1989; 2:349-553.
20. Sevelius H, Runkel R, Segre E, Bloomfield SS. Bioavailability of naproxen sodium and its relationship to clinical analgesic effects. Br J Clin Pharmacol 1980; 10(3):259-263.
21. Peck GE, Baley GJ, McCurdy VE, Banker GS. Tablet formulation and design In: Lieberman HA, Lachman L, Schwartz JB, eds. Pharmaceutical Dosage Forms: Tablets Vol. 1. New York: Marcel Dekker Inc. 1989; 1:73-130.
22. Banaker UV. Pharmaceutical Dissolution Testing. New York: Marcel Dekker, Inc., 1991:133-187.
23. Solvang S, Finholt P. Effect of tablet processing and formulation factors on dissolution rate of the active ingredient in human gastric juice. J Pharm Sci 1970; 59(1):49-52.
24. Pinnamaneni S, Das NG, Das SK. Formulation approaches for orally administered poorly soluble drugs. Pharmazie 2002; 54:291-300.
25. Schwier JB, Cooke GG, Hartauer KJ, Yu L. Rayon: A source of fural-a reactive aldehyde capable of insolubilizing gelatin capsules. Pharm Technol 1993:78-80.
26. Lee TWY, Robinson JR. Controlled-Release Drug Delivery Systems. In: Gennaro AR, ed. Remington: The Science and Practice of Pharmacy. Philadelphia. Vol. 20. Lippincott Williams & Wilkins 2000; 20:903-929.
27. Yi L. Amorphous pharmaceutical solids: preparation characterization and stabilization. Adv Drug Del Rev 2001; 48:27-42.
28. Bandelin FJ. Compressed tablets by wet granulation. In: Lieberman HA, Lachman L, Schwartz JB, eds. Pharmaceutical Dosage Forms: Tablets. New York: Marcel Dekker, Inc. 1990; 1:199-302.
29. Shangraw RF. Compressed tablets by direct compression. Lieberman HA, Lachman L, Schwartz JB, eds. Pharmaceutical Dosage Forms: Tablets. New York: Marcel Dekker, Inc. 1990; I:195-246.
30. Carstensen JT. Advanced Pharmaceutical Solids. New York: Marcel Dekker, Inc., 2001:427-438.
31. Chang RK, Robinson JR. Sustained Release from Tablets and Particles through Coating. In: Lieberman HA, Lachman L, Schwartz JB, eds. Pharmaceutical Dosage Forms: Tablets. New York: Marcel Dekker, Inc. 1990; 3:199-302.
32. Levy G. Effect of certain tablet formulation factors on dissolution rate of the active ingredient I. importance of using appropriate agitation intensities for In vitro dissolution rate measurements to reflect In vivo conditions. J Pharm Sci 1963; 52:1039-1046.
33. International Conference on Harmonisation, pp. 83041-83063; Guidance on Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substance, Federal Register 65 (251), December 29, 2000, pp. 83059-83061.
34. Hanson WA. Handbook of Dissolution Testing. 2nd ed. Eugene, OR: Aster Publishing Corporation, 1991.
35. Yu L, Wang J, Hussain A. Evaluation of USP Apparatus 3 for dissolution testing of immediate-release products. AAPS PharmSci 2002; 4(1):1-7.
36. Kostewicz ES, Brauns U, Becker R, Dressman JB. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm Res 2002; 19(3):345-349.
37. Nicolaides E, Symillides M, Dressman JB, Reppas C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res 2001; 18(3):380-388.
38. Guidance for Industry: SUPAC-IR: Immediate Release Solid Oral Dosage Forms Scale Up and Post Approval Changes: Chemistry Manufacturing and Controls In vitro Dissolution Testing and In vivo Bioequivalence Documentation Rockville, MD: Food and Drug Administration/Center for Drug Evaluation and Research, 1995.
39. Guidance for Industry: SUPAC-MR: Modified Release Solid Oral Dosage Forms-Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls-In vitro Dissolution and In vivo Bioequivalence Documentation, Rockville, MD: Food and Drug Administration/Center for Drug Evaluation and Research, 1997.
40. Sathe P, Tsong YI, Shah V. In vitro dissolution profile comparison: statistics and analysis model dependent approach. Pharm Res 1996; 13(12):1799-1803.
41. Sathe P, Tsong Yi, Shah, V. In vitro dissolution profile comparison and IVIVR- carbamazepine case. In: Young D, DeVane JG, Butler J, eds. In vitro In vivo Correlations, NewYork: Plenum Press, 1997; 31-42.
42. Tsong Yi, Sathe P, Hammerstrom T, Shah V. Statistical assessment of mean differences between two dissolution data sets. Drug Information J 1996; 30(4):1105-1112.
43. Shah V, Tsong Yi, Sathe P, Liu J-P. In vitro dissolution profile comparison: statistics and analysis of the similarity factor f2. Pharm Res 1998; 15(6):889-896.
44. Rescigno A. Bioequivalence. Pharm Res 1992; 9(7):925-928.
45. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol June 19 9 6:64-74.
46. Seo PR, ShahVP, Polli JP. Novel metrics to compare dissolution Profiles. Pharm Dev Technol 2002; 7(2):257-265.
47. Digenis GA, Gold TB, Shah VP. Crosslinking of gelatin capsules and its relevance to their in vitro/in vivo Performance. J Pharm Sci 1994; 83(7):915-921.
48. Code of Federal Regulations-Title 21 Food and Drugs-Parts 300 to 499, Office of the Federal Register/National Archives and Records Administration: Washington DC 2003:181-182.
49. Guidance for Industry: Waiver of In vivo Bioavailability and Bioequivalence Studies for Immediate Release Dosage Forms Based on a Biopharmaceutics Classification System; Rockville, MD: Food and Drug Administration/Center for Drug Evaluation and Research, 2000.
50. Johnson KC, Swindell AC. Guidance in the Setting of Drug Particle Size Specifications to Minimize Variability in Absorption. Pharm Res 1996; 13(12):1795-1798.
51. Polli JE. Dependence of in vitro-in vivo correlation analysis acceptability model selections. Pharm Dev Technol 1999; 4(1):89-96.
52. Kukura J, Arratia PE, Szalai ES, Muzzio FJ. Engineering tools for understanding the hydrodynamics of dissolution tests. Drug Dev Industrial Pharm 2003; 29(2):231-239.
53. Rainbow Dynamic Dissolution Monitor System Manual, Northvale, NJ: Delphian Technology Inc., 2002; 1-8.
54. Sathe P, Venitz J. Comparison of neural network (NN) and multiple linear regression (MLR) as dissolution predictors. Drug Dev Industrial Pharm 2003; 29(3):349-355.
55. Workman J Jr, Creasy KE, Dohertyl S, Bond L, Koch M, Ullman A, Veltkamp DJ. Process analytical chemistry. Anal Chem 2001; 73(12):2705-2718.